Clinical Trials for Ovarian Cancer

Phase I Trial of CPI-0209 in Combination With Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer receive carboplatin plus oral tulmimetostat (CPI-0209), an investigational EZH2/EZH1 inhibitor, followed by tulmimetostat maintenance. The study evaluates combination dosing and safety, with response and progression-free survival as secondary outcomes.

ClinicalTrials.gov ID: NCT05942300

A Phase 1, First-in-Human Study of CUSP06, a Cadherin-6 (CDH6)-Directed Antibody-Drug Conjugate, in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated advanced solid tumors, including platinum-refractory or platinum-resistant ovarian cancer, receive CUSP06 (AMT-707) monotherapy, an investigational CDH6-directed antibody–drug conjugate that delivers the topoisomerase I inhibitor exatecan. Patients need measurable disease and ECOG performance status 0–1; prior treatment with a topoisomerase I–payload antibody–drug conjugate is excluded.

ClinicalTrials.gov ID: NCT06234423

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: For patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer that recurred within 6 months of platinum chemotherapy, this single-arm study combines carboplatin and paclitaxel with defactinib, an oral FAK/PYK2 inhibitor. Platinum-refractory disease is excluded.

ClinicalTrials.gov ID: NCT03287271

A Phase 1, Open-Label Study of FT836, an Off-the-Shelf CAR T-Cell Therapy, With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors that have progressed after at least one systemic therapy receive FT836, an off-the-shelf, induced pluripotent stem cell–derived CAR T-cell therapy targeting MICA/MICB. FT836 is given alone or with paclitaxel, cetuximab, or trastuzumab, including paclitaxel–antibody combinations.

ClinicalTrials.gov ID: NCT07216105

Phase I Evaluation of Combination CLK/DYRK (Cirtuvivint) Inhibition With PARP Inhibition (Olaparib) in BRCA/HRD Platinum Resistant Ovarian Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For women with platinum-resistant, BRCA-mutated and/or HRD-positive high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer previously treated with platinum chemotherapy and a PARP inhibitor. Treatment combines olaparib with investigational cirtuvivint, a CLK/DYRK inhibitor that alters RNA splicing, to assess tolerability and select a dose and schedule.

ClinicalTrials.gov ID: NCT06856499

Phase I Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced unresectable or metastatic solid tumors after standard therapy, or without a suitable standard option, receive intravenous SYS6043 every 3 weeks. This investigational antibody–drug conjugate targets B7-H3 and delivers a cytotoxic payload; expansion cohorts may include small-cell lung, HR-positive/HER2-negative breast, castration-resistant prostate, and ovarian cancers.

ClinicalTrials.gov ID: NCT07424547

A Phase 1b/2 Open-label Study to Assess the Safety and Efficacy of ASP546C in Participants With CLDN18.2-expressing Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma, Pancreatic Adenocarcinoma or Other Solid Tumor Types

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Open-label multicohort study for patients with CLDN18.2-expressing unresectable locally advanced or metastatic gastroesophageal adenocarcinoma, pancreatic adenocarcinoma, or selected other solid tumors after at least one prior systemic therapy and ECOG 0–1. Participants receive IV ASP546C every 3 weeks, a CLDN18.2-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor payload, with dose evaluation in gastroesophageal cancer and higher-dose cohorts in pancreatic and pan-tumor populations.

ClinicalTrials.gov ID: NCT07488676

An Open-label, Phase 1a/1b, Dose Escalation and Dose Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PHST001 in Adult Patients With Advanced Relapsed and/or Refractory Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolls adults with ECOG 0–1 and advanced relapsed/refractory solid tumors after standard therapy; dose escalation includes broad solid tumors including primary CNS tumors, while expansion focuses on ovarian cancer, endometrial cancer, and cholangiocarcinoma. Treatment is PHST001, a humanized IgG4 anti-CD24 antibody intended to block CD24–Siglec-10 innate immune checkpoint signaling and enhance macrophage phagocytosis, given as monotherapy or with chemotherapy backbones such as paclitaxel, topotecan, doxorubicin, FOLFIRI, FOLFOX, or gemcitabine.

ClinicalTrials.gov ID: NCT06840886

A Phase I First-in-human, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors after progression on, or ineligibility for, standard therapies receive intravenous SIM0505 every 21 days. This CDH6-targeted antibody–drug conjugate delivers a topoisomerase-I inhibitor; dose optimization focuses on platinum-resistant ovarian, primary peritoneal or fallopian-tube cancer, clear-cell or papillary renal cell carcinoma, uterine serous carcinoma, and CDH6-expressing NSCLC adenocarcinoma without an actionable EGFR mutation.

ClinicalTrials.gov ID: NCT06792552

A Phase II Study of (IGFBP-2) Vaccine to Prevent Progression After Serologic Detection of Recurrent Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with ovarian, fallopian tube, or primary peritoneal cancer who have a confirmed CA-125 rise after second- or later-line platinum-based treatment but no measurable disease receive a single carboplatin dose followed by up to three monthly doses of an intradermal IGFBP-2–directed DNA vaccine. The vaccine is designed to induce T-cell responses against IGFBP-2–expressing tumor cells.

ClinicalTrials.gov ID: NCT07495124